NASDAQ:DAWN Day One Biopharmaceuticals (DAWN) Stock Forecast, Price & News $13.38 +0.39 (+3.00%) (As of 09/22/2023 ET) Add Compare Share Share Today's Range$12.90▼$13.4850-Day Range$11.54▼$14.8652-Week Range$10.84▼$25.77Volume730,299 shsAverage Volume916,708 shsMarket Capitalization$1.16 billionP/E RatioN/ADividend YieldN/APrice Target$42.14 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Day One Biopharmaceuticals MarketRank™ ForecastAnalyst RatingModerate Buy2.63 Rating ScoreUpside/Downside215.0% Upside$42.14 Price TargetShort InterestBearish20.35% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingSelling Shares$63,562 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($2.45) to ($2.22) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.60 out of 5 starsMedical Sector855th out of 968 stocksPharmaceutical Preparations Industry399th out of 439 stocks 3.3 Analyst's Opinion Consensus RatingDay One Biopharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.63, and is based on 6 buy ratings, 1 hold rating, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $42.14, Day One Biopharmaceuticals has a forecasted upside of 215.0% from its current price of $13.38.Amount of Analyst CoverageDay One Biopharmaceuticals has only been the subject of 4 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted20.35% of the float of Day One Biopharmaceuticals has been sold short.Short Interest Ratio / Days to CoverDay One Biopharmaceuticals has a short interest ratio ("days to cover") of 13.2, which indicates bearish sentiment.Change versus previous monthShort interest in Day One Biopharmaceuticals has recently decreased by 0.17%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldDay One Biopharmaceuticals does not currently pay a dividend.Dividend GrowthDay One Biopharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for DAWN. Previous Next 1.4 News and Social Media Coverage News SentimentDay One Biopharmaceuticals has a news sentiment score of 0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Day One Biopharmaceuticals this week, compared to 2 articles on an average week. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Day One Biopharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $63,562.00 in company stock.Percentage Held by InsidersOnly 8.80% of the stock of Day One Biopharmaceuticals is held by insiders. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Day One Biopharmaceuticals are expected to grow in the coming year, from ($2.45) to ($2.22) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Day One Biopharmaceuticals is -5.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Day One Biopharmaceuticals is -5.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioDay One Biopharmaceuticals has a P/B Ratio of 2.97. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Day One Biopharmaceuticals (NASDAQ:DAWN) StockDay One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.Read More DAWN Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart DAWN Stock News HeadlinesSeptember 17, 2023 | americanbankingnews.comDay One Biopharmaceuticals (NASDAQ:DAWN) Shares Gap Down to $14.64September 16, 2023 | americanbankingnews.comDay One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Receives Average Recommendation of "Moderate Buy" from BrokeragesSeptember 23, 2023 | Chaikin Analytics (Ad)Buy This Stock for AI Tidal Wave (not NVDA)The internet boom made more millionaires than any tech - Microsoft’s CEO says AI has even more potential. Here’s the #1 stock to buy.September 15, 2023 | msn.comDay One Biopharmaceuticals: NDA Filing Decision Is An Inflection Point To WatchSeptember 13, 2023 | americanbankingnews.comDay One Biopharmaceuticals (NASDAQ:DAWN) Rating Reiterated by Needham & Company LLCSeptember 13, 2023 | americanbankingnews.comDay One Biopharmaceuticals (NASDAQ:DAWN) Given Outperform Rating at WedbushSeptember 12, 2023 | markets.businessinsider.comThe Latest Analyst Ratings for Day One BiopharmaceuticalSeptember 11, 2023 | finance.yahoo.comDay One Announces Updated FIREFLY-1 Data for Tovorafenib and Completion of Rolling NDA Submission to FDA for Relapsed or Progressive Pediatric Low-Grade Glioma (pLGG)September 23, 2023 | Chaikin Analytics (Ad)Buy This Stock for AI Tidal Wave (not NVDA)The internet boom made more millionaires than any tech - Microsoft’s CEO says AI has even more potential. Here’s the #1 stock to buy.September 11, 2023 | markets.businessinsider.comDay One Biopharmaceuticals (DAWN) Gets a Buy from H.C. WainwrightSeptember 11, 2023 | markets.businessinsider.comJonesTrading Sticks to Its Buy Rating for Day One Biopharmaceuticals (DAWN)August 18, 2023 | finance.yahoo.comJeff Bezos Used These Strategies for Business Success: Here’s Why They WorkAugust 16, 2023 | finance.yahoo.comDay One Announces VRK1 License Agreement and Research Collaboration with Sprint BioscienceAugust 12, 2023 | markets.businessinsider.comDay One Biopharmaceuticals (DAWN) Gets a Buy from J.P. MorganAugust 10, 2023 | finance.yahoo.comFMR LLC Reduces Stake in Day One Biopharmaceuticals IncAugust 8, 2023 | finance.yahoo.comDay One Reports Second Quarter 2023 Financial Results and Corporate ProgressJuly 23, 2023 | seekingalpha.comDiving Into Day One BiopharmaceuticalsJuly 13, 2023 | seekingalpha.comDay One Biopharmaceuticals: Uncertain Regulatory Path, Narrow MarketJune 27, 2023 | benzinga.comBoard Member at Day One Biopharmaceutical Acquires Company Stock Options Worth 37,500 SharesJune 17, 2023 | finance.yahoo.comDay One Biopharmaceuticals, Inc. (NASDAQ:DAWN) is favoured by institutional owners who hold 54% of the companyJune 12, 2023 | finance.yahoo.comDay One Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional SharesJune 8, 2023 | finance.yahoo.comBiotech Stock Roundup: GSK Provides Updates, Biogen to Discontinue Study & MoreJune 7, 2023 | msn.comDay One Biopharmaceuticals stock dips on pricing $150M stock offeringJune 7, 2023 | finance.yahoo.comDay One Announces Pricing of Public Offering of Common StockJune 6, 2023 | msn.comWedbush Reiterates Day One Biopharmaceuticals (DAWN) Outperform RecommendationJune 6, 2023 | msn.comHC Wainwright & Co. Maintains Day One Biopharmaceuticals (DAWN) Buy RecommendationJune 5, 2023 | markets.businessinsider.comAnalyst Ratings for Day One BiopharmaceuticalSee More Headlines Receive DAWN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Day One Biopharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address DAWN Company Calendar Last Earnings8/07/2023Today9/22/2023Next Earnings (Estimated)11/06/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:DAWN CUSIPN/A CIK1845337 Webdayonebio.com Phone650-484-0899FaxN/AEmployees124Year FoundedN/APrice Target and Rating Average Stock Price Forecast$42.14 High Stock Price Forecast$54.00 Low Stock Price Forecast$34.00 Forecasted Upside/Downside+215.0%Consensus RatingModerate Buy Rating Score (0-4)2.63 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($2.29) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-142,180,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-46.75% Return on Assets-44.15% Debt Debt-to-Equity RatioN/A Current Ratio18.35 Quick Ratio18.35 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.51 per share Price / Book2.97Miscellaneous Outstanding Shares86,970,000Free Float79,320,000Market Cap$1.16 billion OptionableNot Optionable Beta-2.01 Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesDr. Jeremy Bender M.B.A. (Age 51)Ph.D., CEO, Pres & Director Comp: $900kDr. Samuel C. Blackman M.D. (Age 54)Ph.D., Co-Founder and Head of R&D Comp: $651kMr. Charles N. York II (Age 46)COO, CFO & Sec. Comp: $715kDr. Mike Preigh Ph.D.Chief of Technology OperationsMr. Adam Dubow (Age 56)Gen. Counsel Ms. Jaa RobersonChief People OfficerDr. Davy Chiodin Ph.D.Pharm.D., Chief Devel. OfficerMs. Lauren Merendino M.B.A. (Age 47)Chief Commercial Officer Prof. Raphael F. Rousseau M.D. (Age 54)Ph.D., Chief Medical Officer More ExecutivesKey CompetitorsSage TherapeuticsNASDAQ:SAGEAurinia PharmaceuticalsNASDAQ:AUPHKiniksa PharmaceuticalsNASDAQ:KNSARevance TherapeuticsNASDAQ:RVNCBiohavenNYSE:BHVNView All CompetitorsInsiders & InstitutionsDavidson Kempner Capital Management LPBought 40,000 shares on 9/12/2023Ownership: 0.046%California State Teachers Retirement SystemBought 51,017 shares on 8/21/2023Ownership: 0.070%Legato Capital Management LLCBought 13,696 shares on 8/18/2023Ownership: 0.050%Samuel C BlackmanSold 668 sharesTotal: $9,258.48 ($13.86/share)Jeremy BenderSold 2,996 sharesTotal: $41,524.56 ($13.86/share)View All Insider TransactionsView All Institutional Transactions DAWN Stock - Frequently Asked Questions Should I buy or sell Day One Biopharmaceuticals stock right now? 8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Day One Biopharmaceuticals in the last twelve months. There are currently 1 sell rating, 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" DAWN shares. View DAWN analyst ratings or view top-rated stocks. What is Day One Biopharmaceuticals' stock price forecast for 2023? 8 Wall Street analysts have issued 12-month price objectives for Day One Biopharmaceuticals' stock. Their DAWN share price forecasts range from $34.00 to $54.00. On average, they predict the company's share price to reach $42.14 in the next year. This suggests a possible upside of 215.0% from the stock's current price. View analysts price targets for DAWN or view top-rated stocks among Wall Street analysts. How have DAWN shares performed in 2023? Day One Biopharmaceuticals' stock was trading at $21.52 at the beginning of 2023. Since then, DAWN stock has decreased by 37.8% and is now trading at $13.38. View the best growth stocks for 2023 here. When is Day One Biopharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, November 6th 2023. View our DAWN earnings forecast. How were Day One Biopharmaceuticals' earnings last quarter? Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) issued its quarterly earnings results on Monday, August, 7th. The company reported ($0.61) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.60) by $0.01. What ETFs hold Day One Biopharmaceuticals' stock? ETFs with the largest weight of Day One Biopharmaceuticals (NASDAQ:DAWN) stock in their portfolio include Range Cancer Therapeutics ETF (CNCR).Virtus LifeSci Biotech Clinical Trials ETF (BBC). When did Day One Biopharmaceuticals IPO? (DAWN) raised $126 million in an initial public offering (IPO) on Thursday, May 27th 2021. The company issued 8,400,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Cowen and Piper Sandler acted as the underwriters for the IPO and Wedbush PacGrow was co-manager. What is Day One Biopharmaceuticals' stock symbol? Day One Biopharmaceuticals trades on the NASDAQ under the ticker symbol "DAWN." Who are Day One Biopharmaceuticals' major shareholders? Day One Biopharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include RA Capital Management L.P. (8.98%), Franklin Resources Inc. (4.67%), BlackRock Inc. (4.10%), Braidwell LP (3.87%), State Street Corp (3.86%) and Goldman Sachs Group Inc. (2.75%). Insiders that own company stock include Ai Day1 Llc, Charles N York II, Jeremy Bender, Julie Papanek Grant, Michael Gladstone, Papanek Julie Grant, Pharmaceutical Co Ltd Takeda, Samuel C Blackman, Venture Fund Xi LP Atlas and Xi LP Canaan. View institutional ownership trends. How do I buy shares of Day One Biopharmaceuticals? Shares of DAWN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Day One Biopharmaceuticals' stock price today? One share of DAWN stock can currently be purchased for approximately $13.38. How much money does Day One Biopharmaceuticals make? Day One Biopharmaceuticals (NASDAQ:DAWN) has a market capitalization of $1.16 billion. The company earns $-142,180,000.00 in net income (profit) each year or ($2.29) on an earnings per share basis. How many employees does Day One Biopharmaceuticals have? The company employs 124 workers across the globe. How can I contact Day One Biopharmaceuticals? Day One Biopharmaceuticals' mailing address is 395 OYSTER POINT BLVD STE 217, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is dayonebio.com. The company can be reached via phone at 650-484-0899 or via email at hans@lifesciadvisors.com. This page (NASDAQ:DAWN) was last updated on 9/23/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Day One Biopharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.